Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AdvaMed Anti-Device Tax Campaign Takes Aim At Reconciliation Bill

Executive Summary

The medical device lobby group is targeting lawmakers on the Hill and in key states in a new campaign intended to ensure permanent repeal of the 2.3% device tax is part of a future congressional budget reconciliation bill.

You may also be interested in...



US House 'Problem Solvers,' AdvaMed, Aim To Repeal Device Tax

Two recent efforts to repeal the medical device tax include proposed legislation by a bipartisan "Problem Solvers" group of House members that includes a device-tax repeal provision, as well as an advertising campaign by AdvaMed.

Conference Collaboration Sign Of Growing AdvaMed, MDMA Partnership

While the two US-based medical device lobby groups, AdvaMed and MDMA, may have butted heads in the past, they are showing an increasing level of cooperation, most recently with plans to partner on the upcoming Medtech Conference in San Jose.

AdvaMed Pushes For Trump To Address Device Tax In Joint-Session Address

As president Trump gets ready to make his first address before a joint session of Congress, the largest medical device lobby group is asking him to urge permanent repeal of the medical device tax. The group is also planning to blitz congressional offices this week in a bid to persuade lawmakers to include device-tax repeal in budget-reconciliation negotiations.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT104402

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel